XTL Biopharmaceuticals Ltd (XTLB) stock

XTLBNasdaqPharmaceutical Preparations

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026Score 0/30

$1.60−0.04 (-2.44%)

Close on Nov 13, 2026Market cap $15.14MP/E –Yield –

XTL Biopharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2024 it was 0.7%.

Period	Period end	Value	Change (pts)
FY2024	Dec 31, 2024	0.7%	–

See a number that looks wrong?